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Human neuroblastoma GOT0 and IMR32 cells differentiate into neural cells on treatment with 5-BrdU. Here we report that in association with 
differentiation induced by 5-BrdU, the transcription of HIV-l was activated in both neuroblastoma cell lines. An NF-lcB-like factor was also found 
to be produced in association with the neural cell differentiation of these cells. These results suggest hat, during differentiation of neural cells, 
an NF-xB-like factor was produced, and that when the neural cells are infected with HIV-l the production of NF-rcB results in activation of 
transcription of HIV-l. Thus this NF-rc:B-like factor may be involved in the mechanism causing AIDS dementia. 
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1. INTRODUCTION 
Human immunodeficiency virus (HIV-l) is a cytopa- 
thic retrovirus and is the etiological agent of the 
acquired immunodeficiency syndrome, AIDS [ 1,2]. 
Transcription of HIV-l in stimulated T lymphocytes is 
activated by the binding of NF-FOB to the enhancer of 
HIV- LTR [3]. Infection with HIV- 1 results in depletion 
of T lymphocytes and causes AIDS, which is often asso- 
ciated with cerebral disturbance. Neural cells that are 
susceptible to HIV- 1 have been detected in vitro [4], but 
little is known about the infected cell types or the tran- 
scription-activating factors in brain cells of HIV pa- 
tients. In the present study, we demonstrated the pro- 
duction of a nuclear factor similar to NF-KB during 
differentiation of neural cells. The transcription-activat- 
ing factor, NF-rcB, was originally identified as an en- 
hancer-binding protein for the immunoglobulin x: gene 
[5]. Its DNA binding activity has been demonstrated in 
cells of B-cell lineage [5], activated T cells [3], and differ- 
entiated monocytes [6], but this is the first report of the 
production of this factor and induction of transcription 
of HIV-l in neural cells. This factor may be an impor- 
tant cause of AIDS dementia. 
tained from the Japanese Cancer Research Resources Bank (JCRB). 
RPM1 medium 1640 (RPMI1640). Eagle’s minimum essential medium 
(EMEM) and fetal bovine serum (FBS) were purchased from Gibco. 
Plasmids pCV1 and pCDl2 were provided by Dr. F. Wong-Staal. An 
NF-fcB binding protein detection system was purchased from Gibco- 
BRL. Restriction endonucleases were obtained from BRL and 5-BrdU 
was from Sigma. All other chemicals used were of reagent grade. 
2.2. Cell culture 
Human neuroblastoma GOTO, IMR32 and NIH3T3 cells were 
cultured and maintained in medium containing 45% RPMI1640,45% 
EMEM and 10% FBS. The cells were cultured in the same medium 
with or without 5 PM 5-BrdU (5-bromo-2’-deoxyuridine) for 3 days 
before transfection. For examination of the effect of 5-BrdU on cell 
growth, cells were inoculated at a density of 5 x lo4 cells per well 
(24-well microplates) and cultured with or without 5-BrdU in the same 
medium. After several treatments with 5-BrdU, cells were trypsinized 
and the numbers of viable cells were determined by the Trypan blue 
exclusion test. 
2.3. Transfection and CAT assay 
About 2 x lo5 cells per 6 cm dish were cultured and the medium was 
changed 6 h before transfection. Cells were transfected with the plas- 
mid pSV2-CAT [7], pCDlZ(HIV-LTR-CAT) [8] on pCVl(HIV-tat 
expression vector) [9] by calcium phosphate co-precipitation [lo]. For 
competition assay, excess amounts of HIV-l LTR fragments were 
co-transfected with pCD12. The medium was changed 18 h after 
transfection and culture was continued for 30 h. Then the cells were 
collected, washed with phosphate-buffered saline (PBS) and 2 x lo5 
cells were suspended in 0.25 M Tris-HCl (pH 8.0), and cellular extracts 
were prepared by five cycles of freezing (-SO’C) and thawing. 
2. MATERIALS AND METHODS 
2.1. Materials 
The human neuroblastoma cell lines used in this study were ob- 
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Chloramphenicol acetyl transferase (CAT) activity was measured 
by incubating whole cell extracts with “C-labelled chloramphenicol 
and 5 mM acetyl co-enzyme A at 37°C for 18 h. Acetylated chloram- 
phenicol was separated from non-acetylated chloramphenicol by as- 
cending thin-layer chromatography. Chromatograms were examined 
with a Fuji image analyzer BA 100. 
2.4. Assay of binding of nuclear proteins to the NF-rcB binding motif 
Proteins binding to the NF-KB DNA motif were detected by the 
Published by Elsevier Science Publishers B. V. 201 
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C&co-BRL protocol. Briefly, 42mer DNA containing two NF-KB 
DNA motif (GGGGACTTTCC), was end-labeled with [y-32P]ATP 
for binding with nuclear extracts. Nuclear extracts were prepared by 
the method of Dignam et al. [11] after treatment with 5-BrdU for 3 
days. Samples of 5 ng of end-labeled DNA fragments were bound with 
3 pug of nuclear proteins in a solution of 20 mM HEPES buffer (pH 
7.9), 100 mM KCl, 20% (v/v) glycerol, 0.2 mM EDTA, 0.5 mM DTT, 
10 mM MgCl,, 125 mM spermidine and 3 pg poly(dI-dC) for 20 min. 
The preparations were then separated by electrophoresis in a 4% 
polyacrylamide gel in Tris-borate-EDTA buffer and autoradiogra- 
phed. For competition assays, excess amounts of cold 42mer 
fragments and synthesized mutant of NF-KB motif 
(TCGACAGAATICACTTTCCGAGAGGCTCGA) [12] were used 
for binding assays. 
2.5. Binding assay of nuclear proteins with HIV-LTR DNA 
HIV-LTR DNA was digested with Sac1 and PvnII to a 120 bp DNA 
fragment (fr120). This 120 bp fragment, which contained the NF-lcB 
binding motif, was end-labelled with [y-32P]ATP for binding with 
nuclear extracts. Band shift assays for binding with nuclear proteins 
from neuroblastoma cells treated with 5-BrdU were performed as 
described above. 
After band shift assay, shifted bands were removed and eluted from 
the gel by electrophoresis. The obtained protein-DNA complexes 
were immunoprecipitated by anti-NF-lcB ~65 rabbit serum (Santa 
Cruz Biotech. Inc.), and the recovery of the radioactivities of 32P- 
labelled DNA was determined. 
3. RESULTS AND DISCUSSION 
3.1. Cell growth on 5-BrdU treatment 
Human neuroblastoma GOT0 [13] and IMR32 [14] 
cells are known to be prevented from growth and differ- 
entiation into glial or nerve cells by treatment of 5-BrdU 
[15,16]. We examined the effects of 5-BrdU on the 
growth of GOTO, IMR32 and NIH3T3 cell lines. As 
shown in Fig. 1, 5-BrdU at 5 ,&nl inhibited the growth 
of NIH3T3 cells slightly and the growth of GOT0 and 
IMR32 cells moderately. GOT0 and IMR32 cells grew 
slowly from day 2 of treatment, reaching only about 
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Fig. 1. Effect of 5-BrdU on the growth of GOTO, IMR32 and 
NIH3T3 cells in culture. Cells were subcultured at 5 x 10“ cells/flask 
for 2 days and then incubated with (0) or without (0) 5 pug/ml 5-BrdU 
for 5 days. Numbers of viable cells were determined by the Trypan 
blue exclusion test. Values are means f S.E.M. (bars) for 4 experi- 
ments. 
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Fig. 2. Transcriptional activation of HIV-LTR by 5-BrdU treatment 
in GGTO, IMR32 and NIH3T3 cells measured as CAT activity. (A) 
Thin-layer chromatography after analysis of CAT activity in cells 
transfected with pSV2CAT, pCDl2(HIV-LTR-CAT) or pCDl2 plus 
pCVl(HIV-tat expression vector). (B) Decrease of CAT activity by 
competition with excess amounts of HIV-LTR fragments. CAT activ- 
ities were measured in 5-BrdU-treated GOT0 and IMR32 cells trans- 
fected with pCD12 with excess amounts of HIV-LTR DNA (HIV- 
3’LTR EcoRI-Hind111 fragment, cf. Fig. 4A). 
15% of the control growth level on day 5. The viabilities 
of the 3 cell lines treated with 5-BrdU were about 90% 
or more. Before treatment, GOT0 cells were small and 
spindle shaped, but during 3 days of treatment with 
5-BrdU they became larger and flattened out (cf. [16]). 
This flattening was thought to represent differentiation 
of the cells into glial cells. These cells were observed by 
phase-contrast microscopy after 3 days treatment with 
5-BrdU. In subsequent experiments we used GOT0 and 
IMR32 cells after the appearance of large, flattened 
cells. 
3.2. Transcriptional activation of HIV-l in 5-BrdU- 
treated neuroblastoma cells 
Cells were cultured in the presence or absence of 5- 
BrdU for 3 days and then transfected with DNAs of 
pCD12(HIV-LTR-CAT), pCD12 with pCVl(HIV-1 tat 
expression vector), or pSV2-CAT. The cells were har- 
vested 48 h after transfection and 2 x 10’ cells were 
collected, and their CAT activities were measured (Fig. 
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2A). The CAT activity, the percentage conversion of the 
acetylated form of chloramphenicol, of GOT0 cells 
transfected with pCD12 cultured in the presence of 5- 
BrdU was about 63.5%, and the same cells in the ab- 
sence of 5-BrdU was 4.8%. Transfection with the tat 
gene together with pCD12 increased the percentage 
conversion of the acetylated form by 51.3% (Fig. 2A). 
Treatment with 5-BrdU also elevated the CAT activity 
(89.2%). On transfection with the same genes, IMR32 
cells before and after differentiation induced by 5-BrdU 
showed the same response, i.e. elevation of CAT activ- 
ity, as those in GOT0 cells. In NIH3T3, CAT activity 
did not increase on transfection of pCD12 after treat- 
ment with 5-BrdU. This result supports the findings that 
the elevation of CAT activity that appeared in GOT0 
and IMR32 cells was not induced by 5-BrdU but by cell 
differentiation triggered by 5-BrdU. Once differentia- 
tion had been induced by 5-BrdU, cells showed similar 
high CAT activities in media with and without 5-BrdU 
(data not shown). To exclude the possibility that these 
results were due to ‘read through’ by the pCD12 DNA, 
we co-transfected the GOT0 cells and IMR32 with 
pCD12 and HIV-LTR DNA as a competitor. An in- 
crease in the amount of competitor DNA (HIV-LTR) 
resulted in a marked decrease in CAT activity by com- 
petition with HIV-LTR (Fig. 2B). Thus the increase of 
CAT activity observed in differentiating GOT0 and 
IMR32 cells was concluded not to be due to ‘read 
through’, but to transcriptional activation. These results 
suggested that during differentiation, GOT0 and 
IMR32 cells may produce a transcription-activating 
factor(s) that associates with HIV-LTR. 
3.3. NF-KB DNA motif binding protein induced in 5- 
BrdU-treated neuroblastoma cells 
Binding proteins with a NF-KB DNA motif were de- 
tected with a Gibco-BRL kit. A 42mer DNA containing 
two GGGGACTTTCC motifs was end-labeled with 
+++-+++-+-- 
5-BrdU 
Fig. 3. Binding of the 42mer NF-KB DNA binding motif with nuclear 
proteins of 5-BrdU-treated cells. A 42mer DNA from Gibco-BRL was 
end-labeled and used for binding assays. q , with 50-fold excess of 
unlabeled 42mer DNA added during the band shift assay. n , with 
50-fold excess of unlabeled mutant NF-XB motif added during the 
band shift assay. The arrowhead indicates the shifted bands. 
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Fig. 4. Binding of HIV-LTR DNA fragments with nuclear proteins 
of S-BrdU-treated cells. (A) The used 120 bp DNA fragment cut from 
HIV-LTR DNA with Sac1 and PvuII. The 120 bp DNA fragment was 
used for binding assays. (B) Band shift assays of nuclear extracts with 
the 120 bp DNA. q , with 50-fold excess of unlabeled 120 bp DNA 
added during the band shift assay. n , with 50-fold excess of unlabeled 
mutant NF-KB motif added during the band shift assay. The arrow- 
head indicates the shifted bands. 
[y-32P]ATP, and added to nuclear proteins extracted 
from GOTO, IMR32, NIH3T3 and PMA-activated 
Jurkat cells that had been incubated with or without 
5-BrdU for 3 days. Then 42mer DNA fragments were 
separated by electrophoresis and their mobility shifts 
were examined. No band shift was observed after incu- 
bation with the nuclear extract of NIH3T3 incubated 
with or without 5-BrdU or with those of undifferenti- 
ated GOT0 and IMR32 cells cultured without 5-BrdU, 
but nuclear proteins from differentiated GOT0 and 
IMR32 cells (cultured in 5-BrdU) bound with the 42mer 
DNA fragment (Fig. 3). A shifted band of the same size 
was also observed after incubation with the nuclear 
extract of PMA-activated Jurkat cells, which produce 
NF-KB (Fig. 3). The shifted band disappeared on addi- 
tion of a 50-fold excess of unlabeled 42mer fragments 
but it did not disappear on addition of a 50-fold excess 
of unlabeled mutant NF-KB motif (cf. section 2) (Fig. 
3). These results strongly suggested that neuroblastoma 
cells produce an NF-KB-like transcription-activating 
factor during differentiation. 
3.4. Binding of the SBrdU-induced NF-fcB-like factor to 
HIV-LTR DNA 
To examine the binding activity of the transcription- 
activating element in HIV-LTR, we separated a 120 bp 
203 
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fragment containing the NF-KB binding DNA motif 
[17] of HIV-LTR (Fig. 4A), end-labeled it and incu- 
bated it with nuclear protein extracts from GOTO, 
IMR32, NIH3T3 and PMA-activated Jurkat cells with 
or without 5-BrdU treatment. The 120 bp DNA frag- 
ments were then separated by electrophoresis and mo- 
bility shifts were examined. Essentially the same results 
were obtained for the NF-rcB DNA binding motif of 
HIV-LTR. A shifted band was observed only in nuclear 
extracts of PMA-activated Jurkat cells and GOTO, 
IMR32 cells treated with 5-BrdU (Fig. 4B). After band 
shift assay, shifted bands were removed and eluted from 
the gel by electrophoresis. The radioactivities of the 
eluted protein-DNA complexes were 1,783 cpm 
(GOTO; treated with 5-BrdU), 1,695 cpm (IMR32; 
treated with 5-BrdU) and 2,345 cpm (Jurkat; treated 
with PMA). Then, these protein-DNA complexes were 
treated with anti-NF-FcB ~65 rabbit serum and im- 
munoprecipitated. The recovered radioactivities were 
1,406, 1,361 and 2,023 cpm, respectively. The recovery 
of radioactivity of these shifted bands was around 80%. 
These results also indicated that neuroblastoma cells 
produce an NF-%B or NF-rcB-like factor during differ- 
entiation and that the transcription-activating factor 
could bind to the HIV-LTR region. 
The presence of an NF-KB or NF-rcB-like factor in 
differentiated human neural cells may be indicative of 
replication of HIV-l in neural cells. The CD4 molecule 
is a receptor of HIV [18], but CD4-negative brain gli- 
oma cells have also been shown to be infected with HIV 
[ 191. Recently, GalC (galactosyl ceramide) was found to 
play a role in HIV entry into neural cells [20]. Differen- 
tiated GOT0 and IMR32 cells, which also do not ex- 
press CD4 (data not shown), may be susceptible to 
infection with HIV and so be able to activate HIV tran- 
scription by an NF-rcB-like factor. Together with infil- 
tration by macrophages, proliferation of HIV in neu- 
ronal cells may be a cause of progressive degeneration 
of the central nervous system in AIDS patients. 
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